Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics Board Approves $3M Stock Repurchase Program

NEW YORK (GenomeWeb News) - Strategic Diagnostics said today that its board of directors has approved a program to repurchase up to $3 million of the company's outstanding shares of common stock over the next 12 months.
 
"We believe that our stock price does not reflect our belief in the long term value of Strategic Diagnostics,” Francis DiNuzzo, president and CEO, said in a statement. “A repurchase program will benefit SDI's shareholders and demonstrates our board's and management team's confidence in our business.”
 
The company’s shares have plummeted more than 80 percent over the last 12 months, reaching a 52-week low of $1.09 on Oct. 15. In mid-afternoon trading today, shares were up $4.5 percent to $1.39.
 
Strategic Diagnostics said the stock repurchase program will be funded with working capital. The company has cash, cash equivalents, and marketable securities of approximately $11 million and approximately 20.4 million shares of common stock outstanding.
 
The repurchases may be made on the open market, in block trades, or otherwise, and the program may be suspended or discontinued at any time, the company said.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.